TY - JOUR
T1 - desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
AU - Irwin, Nigel
AU - Franlin, ZJ
AU - O'Harte, Finbarr
PY - 2013/4/2
Y1 - 2013/4/2
N2 - Glucagon is hormone secreted from the pancreatic alpha-cells that is involved in blood glucose regulation. As such, antagonism of glucagon receptor signalling represents an exciting approach for treating diabetes. To harness these beneficial metabolic effects, two novel glucagon analogues, desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon, has been evaluated for potential glucagon receptor antagonistic properties. Both novel peptides were completely resistant to enzymatic breakdown and significantly (P
AB - Glucagon is hormone secreted from the pancreatic alpha-cells that is involved in blood glucose regulation. As such, antagonism of glucagon receptor signalling represents an exciting approach for treating diabetes. To harness these beneficial metabolic effects, two novel glucagon analogues, desHis1Glu9-glucagon-[mPEG] and desHis1Glu9(Lys30PAL)-glucagon, has been evaluated for potential glucagon receptor antagonistic properties. Both novel peptides were completely resistant to enzymatic breakdown and significantly (P
U2 - 10.1016/j.ejphar.2013.03.041
DO - 10.1016/j.ejphar.2013.03.041
M3 - Article
SN - 1879-0712
VL - 709
SP - 43
EP - 51
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -
